JOHN C REED
CIK 1181561 · EVP, Innovative Medicine, R&D · last filed 2026-08-18
JOHN C REED is an EVP, Innovative Medicine, R&D who has filed 34 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for MDGL, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$20.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $348.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$348.5K
6
34
-$20.82M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 647 | $538.71 | $348.5K | $0 | 1 | 2026-08-18 |
| JOHNSON & JOHNSON (JNJ.WD) Delisted | EVP, Innovative Medicine, R&D | 24,911 | — | — | -$20.42M | 10 | 2026-05-04 |
| JNJ | EVP, Pharmaceuticals R&D | — | $271.19 | — | $0 | 1 | 2023-05-02 |
| IONIS PHARMACEUTICALS INC (ISIS) Delisted | Director | 0 | — | — | -$402.2K | 9 | 2012-09-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | — | $0.08 | — | $0 | 1 | 2012-06-15 |
| PHARMION CORP (PHRM) Delisted | Director | — | — | — | $0 | 1 | 2007-06-07 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-18 | MDGL | Grant (A) | +647 | $0 | EDGAR |
| 2026-05-04 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +14,253 | -$2.53M | EDGAR |
| 2026-02-18 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | — | -$5.22M | EDGAR |
| 2026-02-17 | JNJ | Notice (144) | −53,931 | -$13.11M | EDGAR |
| 2025-10-20 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | — | -$755.6K | EDGAR |
| 2025-10-17 | JNJ | Notice (144) | −21,721 | -$4.19M | EDGAR |
| 2025-07-18 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Sell (S) | −19,137 | -$3.13M | EDGAR |
| 2025-07-17 | JNJ | Notice (144) | −19,137 | -$3.13M | EDGAR |
| 2025-05-05 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Mixed | +14,253 | -$1.72M | EDGAR |
| 2025-02-19 | JOHNSON & JOHNSON (JNJ.WD) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.